Jean-Baptiste Vulsteke, Petra De Haes, Minoru Satoh, Ben Van Cleynenbreugel, Benoit Beuselinck, Xavier Bossuyt, Ellen De Langhe
{"title":"Anti-TIF1-beta autoantibody-positive dermatomyositis: a case-based review.","authors":"Jean-Baptiste Vulsteke, Petra De Haes, Minoru Satoh, Ben Van Cleynenbreugel, Benoit Beuselinck, Xavier Bossuyt, Ellen De Langhe","doi":"10.1007/s00296-025-05886-4","DOIUrl":null,"url":null,"abstract":"<p><p>To describe the clinical features and cancer risk in patients with dermatomyositis (DM) and anti-TIF1β autoantibodies without other DM-specific autoantibodies (anti-TIF1β-monospecific DM) through a case-based review. Case report of anti-TIF1β-monospecific cancer-associated DM and literature review of cases of anti-TIF1β-monospecific DM. We describe a case of a person with cancer-associated DM in whom we identified anti-TIF1β autoantibodies through immunoprecipitation-mass spectrometry. He had typical cutaneous involvement, mild myositis and a good response to medical therapy after curative treatment of an underlying renal cell cancer. A literature search of Pubmed and Scopus identified 9 more persons with anti-TIF1β-monospecific DM revealing a homogeneous phenotype with typical cutaneous involvement, mild to absent muscular involvement and absence of interstitial lung disease. Two out of ten (20%) had cancer-associated DM. Anti-TIF1β-monospecific DM represents a homogeneous subset of DM characterized by typical cutaneous involvement, mild to absent myositis and potentially an elevated cancer risk (20%). More cohort studies with adequate detection methods are needed to formally assess the cancer risk as compared to anti-TIF1γ and other DM-specific autoantibodies.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"131"},"PeriodicalIF":3.2000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00296-025-05886-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
To describe the clinical features and cancer risk in patients with dermatomyositis (DM) and anti-TIF1β autoantibodies without other DM-specific autoantibodies (anti-TIF1β-monospecific DM) through a case-based review. Case report of anti-TIF1β-monospecific cancer-associated DM and literature review of cases of anti-TIF1β-monospecific DM. We describe a case of a person with cancer-associated DM in whom we identified anti-TIF1β autoantibodies through immunoprecipitation-mass spectrometry. He had typical cutaneous involvement, mild myositis and a good response to medical therapy after curative treatment of an underlying renal cell cancer. A literature search of Pubmed and Scopus identified 9 more persons with anti-TIF1β-monospecific DM revealing a homogeneous phenotype with typical cutaneous involvement, mild to absent muscular involvement and absence of interstitial lung disease. Two out of ten (20%) had cancer-associated DM. Anti-TIF1β-monospecific DM represents a homogeneous subset of DM characterized by typical cutaneous involvement, mild to absent myositis and potentially an elevated cancer risk (20%). More cohort studies with adequate detection methods are needed to formally assess the cancer risk as compared to anti-TIF1γ and other DM-specific autoantibodies.
期刊介绍：
RHEUMATOLOGY INTERNATIONAL is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases. It is designed to serve researchers and clinicians in the field of rheumatology.
RHEUMATOLOGY INTERNATIONAL will cover all modern trends in clinical research as well as in the management of rheumatic diseases. Special emphasis will be given to public health issues related to rheumatic diseases, applying rheumatology research to clinical practice, epidemiology of rheumatic diseases, diagnostic tests for rheumatic diseases, patient reported outcomes (PROs) in rheumatology and evidence on education of rheumatology. Contributions to these topics will appear in the form of original publications, short communications, editorials, and reviews. "Letters to the editor" will be welcome as an enhancement to discussion. Basic science research, including in vitro or animal studies, is discouraged to submit, as we will only review studies on humans with an epidemological or clinical perspective. Case reports without a proper review of the literatura (Case-based Reviews) will not be published. Every effort will be made to ensure speed of publication while maintaining a high standard of contents and production.
Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
